- (2019): Visconti MJ+, Int J Dermatol Dec, Epub ahead of print [REVIEW]
- (2012): Massay RJ+, West Indian Med J 61(7), 743 (3 cases)
Adverse reactions attributed to entire drug class 'HMG-CoA reductase inhibitor / statin'
Statins: very infrequent reports of myasthenia gravis
Advice from the Medicines and Healthcare products Regulatory Agency (MHRA) UK, September 2023
Globally, there has been a very small number of reports of new-onset or aggravation of pre-existing myasthenia gravis with atorvastatin, pravastatin, lovastatin, fluvastatin, simvastatin, rosuvastatin and pitavastatin (single-ingredient and fixed-dose combination products). Advise patients taking statins to be alert to new symptoms for myasthenia gravis, or worsening symptoms of pre-existing myasthenia gravis, and to seek medical advice if these occur.
Please login to view adverse reactions.
- (2019): Tan B+, Expert Rev Clin Pharmacol Apr, Epub ahead of print [REVIEW]
Neurological adverse effect / neurological deficit
- (2024): Li J+, Endocr Metab Immune Disord Drug Targets Oct, Online ahead of print (association) (pharmacovigilance / pharmacoepidemiology)
- (2022): Attardo S+, Int J Mol Sci 23(15), 8364 [REVIEW]
Neuropsychiatric / neuropsychological adverse effect
- (2014): Tuccori M+, CNS Drugs 28(3), 249-72 [REVIEW]
Diabetes mellitus (includes type 1 and type 2 diabetes mellitus)
- (2025): Zheng D+, Curr Pharm Des Sep, Online ahead of print [REVIEW] (association) (pharmacovigilance / pharmacoepidemiology)
- (2020): Qasim Agha O+, BMJ Case Rep 13(2), e232391 (1 case)
Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)
- (2024): Wang B+, Front Pharmacol Jan (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
- (2023): Su FY+, Horm Metab Res Nov, Online ahead of print (with concomitant medication)
- (2020): Meurer L+, Clin Liver Dis 24(1), 107 [REVIEW]
- (2017): Naiqiong W+, Med Sci Monit 23, 5760
- (2016): Wang LY+, Br J Clin Pharmacol 82(3), 823
Pancreatitis / acute pancreatitis
- (2015): Kuoppala J+, Pharmacoepidemiol Drug Saf 24(10), 1085 [REVIEW] (association) (pharmacovigilance / pharmacoepidemiology)
- (2026): Blümel JE+, Menopause Jun, Online ahead of print (association / contributary factor)
Myalgia/Myositis/Myopathy/Myotoxicity
- (2026): Stäuble CK+, Eur J Clin Pharmacol 82(3), 85 (drug interaction) (pharmacovigilance / pharmacoepidemiology)
- (2025): Alshammari AS+, Ther Clin Risk Manag 21, 861-867 (association; with ticagrelor) (drug interaction)
- (2025): Oni-Orisan A+, Pharmacoepidemiol Drug Saf 34(11), e70240
- (2025): Prieto-Peña D+, Int J Mol Sci 26(22), 11144 (pharmacogenomics)
- (2025): Sridharan K+, Curr Rev Clin Exp Pharmacol Mar, Online ahead of print [REVIEW] (pharmacogenomics)
- (2023): Wei C+, J Clin Med 12(10), 3548 (with daptomycin; association)
- (2023): Yow HY+, Asian Biomed (Res Rev News) 17(3), 95-114 [REVIEW] (pharmacogenomics)
- (2021): Alzueta N+, Eur J Hosp Pharm 28(2), 115-117 (1 case)
- (2020): Kee PS+, Front Genet (e-Collection) (pharmacogenomics)
- (2020): Nikolic D+, Expert Opin Drug Saf Apr, Epub ahead of print [REVIEW]
- (2018): Kosinski C+, Rev Med Suisse (French) 14(596), 462 [REVIEW]
- (2017): Millan J+, Clin Investig Arterioscler (Spanish) 29(1), 778%
- (2017): Nazir S+, J Clin Rheumatol 23(3), 149 [REVIEW] (autoimmune myopathy)
- (2014): Jiang Y+, Zhonghua Xin Xue Guan Bing Za Zhi (Chinese) 42(11), 905
- (2013): Mohassel P+, Muscle Nerve 48(4), 477 [REVIEW] (autoimmune myopathy)
- (2011): Abd TT+, Expert Opin Drug Saf 10(3), 373 [REVIEW]
- (2023): Drug Ther Bull 62(1), 4, Online ahead of print
Necrotizing myopathy (includes Statin-induced necrotizing autoimmune myopathy)
- (2022): Ganta N+, Cureus 14(2), e22273 (1 case / male)
- (2022): Somagutta MKR+, Reumatologia 60(1), 63-69 [REVIEW]
- (2021): Fidalgo C+, Acta Med Port Sep, Online ahead of print (2 cases)
- (2020): Huda SA+, Proc (Bayl Univ Med Cent) 34(1), 185-186 (1 case / male)
- (2020): Meyer A+, Arthritis Res Ther 22(1), 5 (55 cases)
- (2017): Tiniakou E+, Curr Opin Rheumatol 29(6), 604-611 [REVIEW]
- (2013): Hamann PD+, Autoimmun Rev 12(12), 1177-81 [REVIEW]
- (2022): Kunakorntham P+, BMC Med Inform Decis Mak 22(1), 233
- (2021): Safitri N+, Drug Healthc Patient Saf 13, 211-219 [REVIEW]
- (2016): Ambapkar SN+, J Assoc Physicians India 64(7), 93
- (2015): Simons JE+, J Clin Lipidol 9(4), 594
Statin-associated muscle symptoms
- (2025): Alshammari AS+, Ther Clin Risk Manag 21, 861-86720% (with ticagrelor) (drug interaction)
- (2025): Breining P+, Ugeskr Laeger (Danish) Oct (e-Collection) [REVIEW]
- (2015): Dobrzynski JM+, Curr Atheroscler Rep 17(2), 477 [REVIEW] (possible association)
- (2014): Wise SJ+, Can J Cardiol 30(12), 1613
- (2015): Bahrami B+, Med J Aust 203(9), 365 [REVIEW]
- (2015): Mizranita V+, Int J Clin Pharm 37(5), 844-50 [REVIEW]
Adverse effects / adverse reactions
- (2026): Zeng Y+, Expert Opin Drug Saf Apr, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
- (2025): Lee DH+, Cardiovasc Toxicol Aug, Online ahead of print [REVIEW] (pharmacogenomics)
- (2025): Maruyama H+, Ther Innov Regul Sci Dec, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
- (2021): Lin JL+, J Atheroscler Thromb Sep, Online ahead of print
- (2021): Yee J+, J Pers Med 11(7), 677 [REVIEW] (pharmacogenomics)
- (2020): Conte C+, Fundam Clin Pharmacol Feb, Epub ahead of print [REVIEW]
- (2020): Mulchandani R+, Expert Opin Drug Saf Jul, Online ahead of print [REVIEW]
- (2020): Thomas JP+, Eur J Clin Pharmacol Jul, Online ahead of print [REVIEW]
- (2019): Bae HJ+, Korean J Intern Med Aug, Epub ahead of print12%
- (2018): Bellosta S+, Expert Opin Drug Saf 17(1), 25 [REVIEW] (from drug interactions)
- (2017): Atonstad S, Tidsskr Nor Laegeforen (Norwegian) 137(1), 36
- (2015): de Keyser CE+, Eur J Endocrinol 173(2), 155 (low testosterone levels in males)
- (2014): Berta E+, Pharmazie 69(6), 42024% (gastrointestinal)
- (2014): Desai CS+, BMJ 349, g3743 [REVIEW]
- Negative findings
- (2026): Lancet Feb (e-Collection) [REVIEW]
